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A
 
BSTRACT
Background:
 
Hypersensitivity to the group 1 grass
pollen allergens is a significant causative factor in the
onset of symptoms for hay fever sufferers. To better
understand the IgE reactivity of the group 1 allergen
from rye grass pollen, we sought to disrupt potential
conformational IgE epitopes on recombinant (r) Lol p 1
by the specific replacement of the seven cysteine resi-
dues in the protein sequence.
 
Methods:
 
Site-directed mutagenesis on the Lol p 1
coding sequence was used to replace all seven cysteine
residues with serine residues. rLol p 1 and the seven
cysteine variants generated by this method were tested
for comparative human IgE reactivity via western blot
immunoscreening and densitometry.
 
Results:
 
Alteration of the cysteine residues at amino
acid positions 72, 77, 83 and 139 of rLol p 1 was
found to reduce the human IgE binding potential of the
molecule. However, the most consistent reduction in
human IgE reactivity was demonstrated by replace-
ment of C
 
77
 
; human IgE antibodies showed an
average 62.7% reduction in reactivity to this molecule.
 
Conclusions:
 
The present investigation has shown
that at least one of the cysteine residues within the Lol
p 1 protein contributes to the IgE binding properties of
this allergen.
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I
 
NTRODUCTION
 
The grass group 1 pollen allergens, glycosylated pro-
teins of approximately 28–35 kDa,
 
1
 
 are major allergens
with up to 95% of grass pollen allergic individuals
showing immunoreactivity.
 
2
 
 Because homologous pro-
teins have been identified in all grass species tested,
the  group 1 grass pollen allergens are an important
group of immunoreactive proteins.
 
3–6
 
 Cloning and
sequencing of the group 1 pollen allergens from eight
grass species has revealed significant levels of amino
acid conservation, including the presence of seven
strictly conserved cysteine residues within these proteins.
Although functionally and immunologically distinct,
the group 1 grass pollen allergens show conservation of
six of their seven conserved cysteine residues and 25%
overall amino acid homology to expansins, a group of
proteins that induce plant cell wall extension (creep).
 
7
 
On the basis of the extent of amino acid conservation
between the two groups of proteins, the group 1 grass
pollen allergens are predicted to share a similar second-
ary structure to the expansins.
 
8
 
 Furthermore, the degree
of cysteine conservation also suggests a common pattern
of disulfide bond formation and protein folding between
the two groups of proteins. An expansin-like activity has
also been demonstrated for the purified group 1 allergen
from maize pollen.
 
8
 
 Amino acid sequence homology has
been shown between the group 1 allergens and three
functionally important sequence motifs of the C1
(papain-like) family of cysteine proteinases.
 
9
 
 Recently,
Grobe 
 
et al
 
.
 
10
 
 have shown that the group 1 pollen allergen
from Timothy grass demonstrates similar biochemical
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and functional properties to cathepsin B, a member of the
papain (C1) family of cysteine proteinases.
Although the presence of disulfide bonds within group 1
grass pollen allergen molecules has not been demon-
strated specifically, homologies with functional proteins,
such as the expansins and C1 cysteine proteases, suggest
the conservation of certain structural properties, possibly
stabilized by the presence of intramolecular disulfide
bonds. In certain allergen molecules, intramolecular
disulfide bonds participate in the presentation of confor-
mational IgE epitopes on the molecular surface.
 
11
 
Indeed, for the group 2 allergens from house dust mites,
disulfide bonds have been shown to assist in the forma-
tion of conformational IgE epitopes on the molecular
surface.
 
12,13
 
 For Lol p 1, the group 1 pollen allergen from
rye grass, a number of linear IgE-binding epitopes have
been mapped using either synthetic peptides correspond-
ing to linear segments of the allergen or a pool of
monoclonal antibodies to block human IgE binding.
 
14–17
 
Although certain linear regions of rLol p 1 have been
shown to be involved in human IgE antibody interaction,
the presence of potential conformational epitopes on
the  molecular surface of this allergen, as mediated
by intramolecular disulfide bridges between cysteine
residues, is unknown.
Immunotherapeutic treatment of inhalant allergies
traditionally involves the subcutaneous administration
of increasing doses of a crude allergen extract consist-
ing of impure and poorly characterized, allergenic and
non-allergenic proteins.
 
18
 
 Due to the high IgE-binding
properties of native allergens, administration of such
crude protein preparations to sensitive individuals
carries the risk of recipients developing a potentially
life-threatening anaphylactic response.
 
19
 
 With the aim
of developing allergen-specific immunotherapeutic
reagents, recent studies (see Discussion) have shown
the production of highly purified recombinant forms of
native allergens with reduced IgE-binding capacity and
anaphylactogenic potential. The targeted alteration of
recombinant allergens from house dust mite feces
(Der f 2, Der p 2) have recently reported the successful
use of site-directed mutagenesis for the replacement of
cysteine residues to reduce or abolish the IgE reactivity
of these proteins.
 
20,21
 
 In the present investigation, we
sought to determine the importance of the cysteine resi-
dues of rLol p 1 to the overall IgE binding capacity of
this recombinant allergen and, in doing so, generate
potentially hypoallergenic forms of this major rye grass
pollen allergen.
 
M
 
ETHODS
 
Cloning into the expression vector
 
The pMAL-c2 expression vector (Qiagen, Hilden,
Germany) was used for the generation of all rLol p 1
and rLol p 1 variant proteins. The cDNA encoding 
 
Lolp1
 
,
previously cloned from a cDNA expression library,
 
22
 
 was
amplified using specific primers designed to introduce
restriction sites at both ends of the coding region
(5
 
′
 
 primer: GCAGCGCGCATGATATCGCGAAGG;
3
 
′
 
 primer: CACTCCACTGAATTCTCACTTGGCCGAG).
The 
 
Eco
 
RV restriction site introduced into the 5
 
′
 
 end of
the coding region allowed the in-frame ligation into the
 
Xmn
 
I site in the pMAL-c2 multiple cloning site. The
position of the 
 
Eco
 
RV site was designed specifically to
permit factor Xa cleavage of the expressed Maltose-
binding protein (MBP)–allergen fusion complex, allowing
the allergen to be released from the MBP without the
addition of extraneous amino acids. DNA sequencing of
the junction between the 
 
malE
 
 and 
 
Lolp1
 
 coding regions
confirmed the correct 5
 
′
 
 sequence for 
 
Lolp1
 
. All variant
constructs were generated by site-directed mutagenesis
of the pMAL–
 
Lolp1
 
 vector.
 
Site-directed mutagenesis of 
 
Lolp1
 
The 
 
Lolp1
 
 gene in pMAL-c2 was altered by site-directed
mutagenesis at each of the seven cysteine residues
within the Lol p 1 protein (see Fig. 1). In all cases,
primers were designed to alter the coding sequence
from TGC to TCC, with the new codon encoding serine.
 
Fig. 1
 
Linear representation of rLol p 1 and the seven cysteine
variants (C41S, C57S, C69S, C72S, C77S, C83S and C139S)
showing the approximate location of the cysteine residues that
were altered within each molecule.
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The cysteine variants of rLol p 1 are identified according
to the residue altered and, thus, the variant with the
cysteine residue at amino acid residue position 41
altered to serine was identified as C41S, the variant
altered at amino acid residue position 57 was identi-
fied as C57S etc. (see Fig. 1). The forward primers
used for the site-directed mutagenesis of the 
 
Lolp1
 
sequence are listed hereafter: to generate C41S variant,
CGGCGGCGCGTCCGGGTACAAG; C57S GCAT-
GACCGGCTCCGGCAACAC; C69S CGGCCGTGG-
CTCCGGCTCCTGC; C72S CTGCGGCTCCTCCTTC-
GAGATC; C77S GAGATCAAGTCCACCAAGCCCG;
C83S GCCCGAGTCCTCCTCCGGCGAG; and C139S
GGGTCAAGTCCAAGTACCCGG. Reverse primers were
the reverse complement of the forward primers listed.
Site-directed mutagenesis was performed using the
QuikChange mutagenesis kit (Stratagene, La Jolla, CA,
USA) in a volume of 50 
 
µ
 
L containing 0.05 mmol/L each
dNTP, 125 ng each of the forward and reverse primers,
2.5 units 
 
Pfu
 
 polymerase (Promega, Madison, WI, USA)
and the appropriate dilution of the supplied 10
 
×
 
 buffer.
All reactions consisted of an initial denaturation step of
95
 
°
 
C for 30 s, 16 cycles of 95
 
°
 
C for 30 s, 55
 
°
 
C for
30 s and 68
 
°
 
C for 2 min per kb plasmid and then
cooling to 4
 
°
 
C. All reactions were performed in a
GeneAmp 2400 PCR system (Perkin Elmer, Norwalk,
CT, USA). After completion of the reaction, 2 
 
µ
 
L
(20 units) restriction enzyme 
 
Dpn
 
I was added and the
preparation incubated at 37
 
°
 
C for 3 h before transfor-
mation of an aliquot into freshly prepared competent
XL1B cells prepared according to the method of Cohen
 
et al
 
.
 
23
 
Expression and purification of proteins fused to 
MBP
 
A 500 mL aliquot of LB broth containing 0.2% (w/v)
glucose and 100 
 
µ
 
g/mL ampicillin (Sigma Aldrich,
St Louis, MO, USA) was seeded with 10 mL overnight
culture of XL1B cells (Stratagene) housing the appropri-
ate plasmid and grown at 37
 
°
 
C for 4 h. Isopropyl-
 
β
 
D
 
-
thiogalactoside was then added to a final concentration
of 0.3 
 
µ
 
mol/L to induce expression of the fusion protein.
Following incubation at 37
 
°
 
C for a further 2 h, bacterial
cells were harvested by centrifugation at 3840 
 
g
 
 for
10 min. Cells from one 500 mL culture were resus-
pended in 20 mL column buffer (20 mmol/L Tris buffer
(pH 7.4), 200 mmol/L sodium chloride, 1 mmol/L EDTA)
and stored at –20
 
°
 
C overnight. Resuspended cells were
thawed slowly in cold water before sonication six times
for 15 s each (15 s on, 15 s off) in an ice bath at 20 
 
µ
 
m
peak-to-peak using an Mk2–6-76 Sonicator (MSE,
Loughborough, UK). The sonicated preparation was
centrifuged at 9000 
 
g
 
 for 20 min at 4
 
°
 
C. The super-
natant was harvested and added to 3 mL prewashed
amylose resin (New England Biolaboratories, Beverley,
MA, USA). The mixture was rocked gently on ice for 1 h
before centrifugation for 10 s at 700 
 
g
 
 to pellet the
resin. After resuspension in 15 mL column buffer,
the  resin and protein were rocked gently on ice for
10 min. Centrifugation and washing were performed
twice before the resin was poured into a disposable
1 mL column (Qiagen). The resin column was allowed
to form by gravity before washing with a further six
column volumes of column buffer. Fusion proteins were
eluted from the column in two volumes of column buffer
supplemented with 10 mmol/L maltose. Fusion proteins
were visualized by Coomassie staining of 12.5% (w/v)
sodium dodecyl sulfate (SDS)–polyacrylamide gels.
 
24
 
 The
concentration of proteins present in eluted aliquots was
determined according to the method of Bradford
 
25
 
 and
confirmed by SDS–polyacrylamide gel electrophoresis
(PAGE) and Coomassie staining against a protein stand-
ard of known concentration.
 
Factor Xa treatment of fusion proteins
 
Factor Xa used for digestion of MBP from rLol p 1 and
the cysteine variants was purchased from New England
Biolaboratories and used at a concentration of 10 
 
µ
 
g/mg
fusion protein, with digestion allowed to proceed at
4
 
°
 
C with gentle rotating for 5 h. Electrophoresis and
Coomassie staining of a 12.5% (w/v) SDS-polyacryla-
mide gel was used to verify digestion. Digested samples
were stored at –20
 
°
 
C before use.
 
Electrophoresis and western blotting of rLol p 
1 variants
 
Approximately 2 
 
µ
 
g total protein of each of rLol p 1 and
the seven cysteine variants, after factor Xa treatment,
were separated by SDS-PAGE (15% w/v)
 
24
 
 on a mini-
Protean II protein gel system (Bio-Rad, Hercules, CA,
USA) in a buffer of 200 mmol/L glycine, 0.1% (w/v) SDS
and 25 mmol/L Tris buffer (pH 6.8). In a dye composed
of 0.125 mol/L Tris buffer (pH 6.8), 20% (v/v) glycerol
and 50 mmol/L bromophenol blue, proteins were sepa-
rated under non-reducing conditions without prior heat
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denaturing treatment.
 
24
 
 Prior to blotting, a duplicate gel
was tested for the presence of proteins by SDS-PAGE
and Coomassie staining. Duplicate gels were blotted
to  pretreated polyvinyl difluoride (PVDF) membrane
(Osmonics, Westborough, PA, USA) using a mini-
Protean II electroblotting system in a buffer of
200 mmol/L glycine, 25 mmol/L Tris buffer and 20%
(v/v) methanol at 100 V for 70 min. After drying, blots
were blocked in 10% (w/v) milk powder in phosphate-
buffered saline (PBS; 0.15 mol/L sodium chloride,
3.6 mmol/L sodium dihydrogen orthophosphate,
6.7 mmol/L di-sodium hydrogen orthophosphate) for
1 h at room temperature with shaking. After washing
twice in PBST (PBS with 0.05% (v/v) Tween 20) and twice
in PBS for 10 min each, blots were incubated in sera
from grass pollen-allergic patients diluted 1 : 5 in PBS
containing 1% (w/v) bovine serum albumin (BSA) and
0.02% (w/v) sodium azide. After overnight shaking at
room temperature, blots were washed as above and
incubated with an alkaline phosphatase-conjugated
goat, antihuman IgE antibody (diluted 1 : 1000 in PBS
containing 1% (w/v) BSA and 0.02% (w/v) sodium
azide; Sigma). After 2 h shaking at room temperature,
blots were again washed as above and incubated in
0.4 mmol/L nitroblue tetrazolium (Boehringer, Mannheim,
Germany), 0.4 mmol/L 5-bromo-4-chloro-3-indolyl
phosphate 
 
p
 
-toluidine salt (Astral Scientific, Gymea,
NSW, Australia) prepared in a solution of 100 mmol/L
Tris buffer (pH 9.5), 100 mmol/L sodium chloride and
50 mmol/L magnesium chloride. Color development
was halted by incubation in 0.1 mol/L EDTA. For chemi-
luminescense assay, blots were developed using CDP-
Star reagent (Boehringer, Mannheim, Germany) and
exposing to Kodak MR film (Integrated Sciences,
Melbourne, Victoria, Australia). Image densities were
subjected to quantification using Kodak EDAS 120
digital imaging software.
 
R
 
ESULTS
 
Reduced IgE-binding capacity of rLol p 1 
cysteine variants as tested by western blot 
analysis
 
Upon western blotting and immunoscreening of rLol p 1
and the cysteine variants with an anti-Lol p 1 mono-
clonal antibody and a rabbit polyclonal antisera, it could
be seen that the protein products at approximately
33 kDa bound both antibodies (Fig. 2). Furthermore,
the intensity of binding of the antibodies was similar for
rLol p 1 and the seven cysteine variants, indicating that
the same amount of protein product at the size expected
was present for each of the proteins. Immunoscreening
with sera from grass pollen-allergic patients showed the
differing abilities of the rLol p 1 cysteine variants to bind
human IgE antibodies (Fig. 2). Although the rLol p 1
cysteine variants C41S, C57S and C69S appeared to
bind human IgE antibodies at an equivalent or greater
level than rLol p 1, variants C72S, C77S, C83S and
C139S showed a reduced capacity to bind human IgE
antibodies from the sera of certain patients (Fig. 2). The
rLol p 1 cysteine variant C77S showed the lowest level of
human IgE antibody binding of the proteins immuno-
screened with sera from grass pollen-allergic patients
MS, TP and JL (Fig. 2). When rLol p 1 and the seven
cysteine variants were immunoscreened with the diluted
sera from patient DI, cysteine variant C83S showed the
lowest level of human IgE antibody binding. After incu-
bation with the sera from patient RT, human IgE anti-
body binding to cysteine variants C72S, C77S, C83S
and C139S was not visible by the method used.
Western blots were subjected to densitometric analy-
ses to obtain semiquantitative data for the level of human
IgE antibody binding to rLol p 1 and cysteine variants. It is
interesting to note that, for most patients, variant C57S
showed slightly higher level of IgE reactivity compared
with rLol p 1. However, cysteine variants C72S, C77S,
C83S and C139S showed reduced IgE reactivity in most
cases. Of all the variants tested, mutant C77S showed
most prononced reduced IgE-binding capacity compared
with rLol p 1 in all five patient sera tested (Table 1). One
patient (RT) showed as little as 12.5% human IgE anti-
body binding to C77S compared with rLol p 1.
 
D
 
ISCUSSION
 
More than 90% of grass pollen-allergic patients possess
IgE antibodies that recognize the group 1 pollen aller-
gens.
 
2
 
 Furthermore, because proteins homologous to
these allergens have been identified in pollen extracts
from all grasses tested, it is clear that this group of
inhalant allergens has a major impact on the incidence
of grass pollen allergy. The present study investigated
the impact that the seven strictly conserved cysteine
residues of Lol p 1 have on the human IgE-binding
capacity of the recombinant allergen.
Studies predicting the IgE epitopes of Lol p 1 have pre-
viously used either synthetic peptides, corresponding to
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linear segments of this allergen, or a pool of monoclonal
antibodies to block human IgE binding to linear
peptides.14–17 The use of linear synthetic peptides and
monoclonal antibodies to determine the position of IgE
epitopes on allergen molecules is limited in that the pres-
ence of conformational epitopes could be overlooked.
Evidence for the existence of at least one conformational
IgE epitope for Lol p 1 can be gained from a previous
Fig. 2 Western blot immuno-
screening of rLol p 1 and the
seven cysteine variants (C41S,
C57S, C69S, C72S, C77S,
C83S and C139S) with an anti-
group 1 grass pollen allergen
monoclonal antibody and poly-
clonal antisera, and sera from
five grass pollen-allergic patients
(DI, MS, RT, TP and JL). Proteins
of between 29 and 37 kDa are
shown on each blot.
 
Table 1
 
The level of human IgE binding to various cysteine mutants expressed as a percentage of binding to rLol p 1
Cysteine variant
C41S C57S C69S C72S C77S C83S C139S
Patient
DI 102.2 110.4 92.5 80.4 76.8 62.9 76.0
MS 104.0 102.5 65.0 77.0 26.0 70.5 79.0
RT 110.5 130.0 100.0 18.8 12.5 15.5 16.0
TP 100.0 104.0 99.0 91.5 39.0 35.0 35.0
JL 115.0 143.0 143.0 104.5 37.0 105.0 97.0
Mean 106.3 118.0 100.0 74.5 38.3 56.8 59.8
The level of human IgE antibody binding to the C77S variant is significantly reduced from that binding to rLol p 1.
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study using recombinantly expressed Lol p 1 fragments to
inhibit human IgE binding to rLol p 1.
 
17
 
 In this study, two
fragments of Lol p 1, corresponding to amino acids
1–168 and 169–240, could inhibit human IgE antibody
binding to rLol p 1 by 17 and 51%, respectively.
 
17
 
Because these fragments together represent the complete
Lol p 1 molecule, and no known linear IgE epitope has
been mapped across their point of junction, the remain-
ing 32% of human IgE binding not inhibited by these
fragments suggests the presence of at least one con-
formational IgE epitope. The results of the present study
also suggest that one or more of the cysteine residues
present within Lol p 1 may contribute to the formation of
a conformational IgE-binding epitope on this allergenic
protein.
Site-directed mutagenesis of cysteine residues within
rDer p 2 and rDer f 2 has been demonstrated to reduce
the allergenic reactivity of both recombinant house dust
mite allergens.
 
20,21
 
 These studies not only demonstrate
the importance of disulfide bonds to IgE epitope forma-
tion for these proteins, but they also show that disruption
of key disulfide bonds can dramatically reduce the aller-
genic nature of these molecules. Unlike the group 2
house dust mite allergens, the presence of intramolecular
disulfide bonds has not been proven for the group 1
grass pollen allergens. However, the presence of seven
strictly conserved cysteine residues in the protein back-
bone, along with sequence and predicted structural
homologies to functional proteins, implies that the group
1 grass pollen allergens possibly have a conserved
molecular structure, which may be influenced by disulfide
bonds. Our results show that replacement of cysteine res-
idues at positions 41, 57 and 69 has no negative effect
on IgE reactivity of rLol p1. In fact, variant C57S showed
higher levels of IgE reactivity compared with rLol p1. It is
possible that mutation of C57 may have altered the con-
formation of the rLol p1 molecule in such a way that the
linear IgE-binding epitopes of the allergen became more
accessible to these antibodies, thereby increasing the IgE
reactivity of the C57S variant. The results of the present
study suggest that residue C77 of rLol p 1, and also
perhaps those situated at amino acid residue positions
72, 83, and 139, may contribute to the formation of a
structure that is critical for human IgE recognition of rLol
p 1. If cysteine at position 77 was involved in disulfide
bond formation, then another counterpart derivative
should have shown similar reduction in IgE reactivity.
Because no counterpart derivative was observed, it is
possible that cysteine at position 77 is critical in IgE
epitope formation but that it may not participate in
disulfide bond formation, whereas the other six cysteine
residues may form disulfide bonds. As discussed above, it
is also possible that mutation of selected residues may
change the conformation in such a way that linear IgE-
binding epitopes of Lol p 1 become more/less accessible
to human IgE antibodies. Patient-to-patient variability
and the documented presence of linear human IgE
epitopes on rLol p 1 may, together, have led to an incon-
sistent reduction in human IgE binding to ‘the counter-
part’ derivative involved with disulfide bond formation
with cysteine residue 77. The results of the present study
also suggest that individual cysteine residues are not
solely responsible for presentation of the immuno-
dominant IgE epitope of rLol p 1. It is apparent from these
results that other factors, perhaps the presence of linear
IgE epitopes, may also play a role in human IgE recogni-
tion of rLol p 1.
The immunodominant T cell epitope of Lol p 1 has
been identified as the peptide spanning amino acid resi-
dues 193-206.
 
26–28
 
 This peptide, along with a second
mapped T cell epitope spanning amino acid residues
215–229, has been retained in all rLol p 1 variants
generated in the present study. Furthermore, the immuno-
dominant T cell epitope of Phl p 1, the group 1 pollen
allergen from Timothy grass, has been identified as the
peptide spanning amino acids 70–84 of this protein.
 
29
 
Lol p 1 and Phl p 1 share 14 identical amino acids in this
peptide, including three of the seven cysteine residues
strictly conserved in all group 1 grass pollen allergens.
This peptide is altered in cysteine variants C72S, C77S
and C83S; each of these molecules contains one amino
acid residue that differs from the reported sequence.
 
30
 
The effect of these cysteine residues on peptide recog-
nition by T cells is undetermined and, therefore, these
rLol p 1 cysteine variants would need to be tested experi-
mentally to demonstrate the effect of cysteine mutagene-
sis on the ability to stimulate T cell clones recognizing this
region.
Based on the hypothesis that decreasing IgE antibody
binding but maintaining T cell recognition of allergens
will decrease the risk of anaphylaxis while maintaining the
ability to induce an immune response, hypoallergenic
variants of recombinant allergens are now being devel-
oped for use in specific immunotherapy of pollen allergic
diseases. A number of studies have suggested that spe-
cific immunotherapy can be effective when the balance of
cytokines released from T cells is altered with a shift from
an allergic (Th2) to an immunogenic (Th1) response.
 
31,32
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Thus, non-IgE-binding forms of allergens may, in their
capacity to be recognized by T cells but not IgE anti-
bodies, induce a shift in the helper T cell response from
Th2 to Th1. Site-directed mutagenesis has been used
successfully to produce low IgE-reactive recombinant
forms of house dust mite (Der p 2, Der f 2) and pollen
allergens from rye grass (Lol p 5), birch (Bet v 1, Bet v 4)
and oilseed rape (Bra r 1).
 
20,21,33–36
 
 These results have
shown that replacement of very few key amino acids
within an allergen molecule can significantly reduce
the human IgE reactivity of these allergenic proteins. The
results of the present study may aid the development of a
recombinant form of Lol p 1 with reduced human IgE
reactivity and, therefore, may contribute to the develop-
ment of improved immunotherapeutic reagents for the
treatment of grass pollen allergy.
Although the presence of cysteine residues on the
Lol p 1 protein has been known since the cDNA was
cloned and characterized, the specific contribution these
residues make to the allergenicity of the protein has not
been reported. The outcomes of the present study suggest
that at least one of the cysteine residues on the Lol p 1
molecule contributes to the allergenicity of this protein,
either by participating in the formation of a conforma-
tional epitope or in the uniform presentation of linear
epitopes. The group 1 grass pollen allergens are major
contributors to grass pollen allergy in many parts of the
world. Elucidation of the influence of cysteine residues to
allergenicity of rLol p 1 is important for a thorough under-
standing of the immunological properties and allergenic
nature of this allergen. Application of this knowledge,
by the generation of low IgE-binding forms of Lol p 1,
may aid the future development of improved immuno-
therapeutic reagents for the treatment of grass pollen
allergy in individuals sensitive to the group 1 grass pollen
allergens.
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